Us2

𝐓𝐡𝐢𝐬 𝐢𝐬 𝐰𝐡𝐚𝐭 𝐀𝐈 𝐞𝐜𝐡𝐨 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐚𝐜𝐭𝐮𝐚𝐥𝐥𝐲 𝐥𝐨𝐨𝐤𝐬 𝐥𝐢𝐤𝐞 𝐰𝐢𝐭𝐡 𝐔𝐬𝟐.𝐚𝐢. What you are seeing: → Every view automatically identified and classified → Structures traced, measurements calculated → Disease detection in real time → A full structured report. Ready. Zero clicks. FDA cleared. CE marked. Running in clinical workflows across the world today. Curious how our solution could elevate your echo workflow? 👉 Book a demo at us2.ai

New paper in Circulation: Cardiovascular Imaging AI detection of cardiac amyloidosis from a single routine echo view 5,776 patients. UK, Taiwan, US, Japan. Sensitivity 88.5% | Specificity 87.2% | AUC 0.93 AI deep learning vide-based classifier outperforms the multiparametric score (0.93 vs 0.86, p<0.001). 🔗ahajournals.org/doi/10.1161/CI…

𝐄𝐜𝐡𝐨 𝐫𝐞𝐩𝐨𝐫𝐭𝐢𝐧𝐠 𝐬𝐡𝐨𝐮𝐥𝐝𝐧'𝐭 𝐭𝐚𝐤𝐞 𝟒𝟎 𝐦𝐢𝐧𝐮𝐭𝐞𝐬. With Us2.AI, it doesn't. From DICOM to a full structured report. Image identification, measurements, disease detection. Zero clicks. No variability. In real echo workflows, that means: → Faster reporting, more patients seen → Earlier detection of conditions that are easy to miss → Consistent, explainable output every time FDA cleared. CE marked. Running in echo workflows across the world today. What could AI echo elevate in your workflow? 👉 Book a demo at us2.ai

𝐑𝐞𝐚𝐥 𝐰𝐨𝐫𝐥𝐝 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐢𝐦𝐩𝐚𝐜𝐭 𝐰𝐢𝐭𝐡 𝐔𝐬2.𝐚𝐢 At one of Vietnam's cardiac units, an echo diagnosis used to take 35-40 minutes. Now it takes 10. University Medical Center Ho Chi Minh City sees over 15,000 cardiac patients every month. With that kind of volume, every minute saved matters. And so does every diagnosis caught. With Us2.ai, their team is now identifying up to 20% more cases of heart failure with preserved ejection fraction. Cases that used to slip through are now being flagged, in real time, by AI. If you'd like to learn more about how AI echo can help elevate your echo workflow, let's talk. 👉 Book a demo at us2.ai

The 2026 JACC Cardiovascular Statistics report just dropped. Some of these numbers are hard to look away from. Age-adjusted heart failure mortality declined from 1999 to 2011, but has since reversed, with 2021 rates higher than 1999. Plus: 📌 Hypertension-related CV deaths nearly doubled over 20 years 📌 Only 1 in 2 eligible heart disease patients gets optimal medical therapy The treatments exist. The guidelines exist. The challenge is reaching patients early enough. AI-powered echo is helping. Faster analysis, more consistent reporting, more patients caught earlier. And with AI-assisted POCUS, cardiac assessment is moving beyond hospitals into community care, primary care, and remote settings. That's what we're building at Us2.ai, and we aim to close the gap. What stood out most to you from the report? 👇 📊JAAC Stats: jacc.org/doi/10.1016/j.…

𝐌𝐚𝐫𝐜𝐡 𝐢𝐬 𝐀𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡! For the cardiology community, this carries a particular significance. Cardiac amyloidosis is one of the most frequently missed diagnoses. Patients present for years with breathlessness, fatigue and thickened heart walls before anyone connects the dots. By then, the window for early intervention has often narrowed considerably. This is no longer a disease without answers. Effective therapies now exist for ATTR and AL cardiac amyloidosis. The barrier is no longer treatment. It is finding patients early enough to benefit. This month, we are proud to spotlight our published validation study in Circulation: Cardiovascular Imaging, of an AI model designed to close that gap: automated cardiac amyloidosis detection from a single routine echo view, validated across globally diverse patient cohorts. 📖 Read the full paper: us2.ai/clinical-evide…

🔬 𝐖𝐞’𝐯𝐞 𝐚𝐥𝐰𝐚𝐲𝐬 𝐛𝐞𝐞𝐧 𝐠𝐫𝐨𝐮𝐧𝐝𝐞𝐝 𝐢𝐧 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞. 𝐍𝐨𝐰 𝐢𝐭’𝐬 𝐞𝐯𝐞𝐧 𝐞𝐚𝐬𝐢𝐞𝐫 𝐭𝐨 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐨𝐮𝐫𝐬. Our upgraded Clinical Evidence page brings together the validation studies behind our software alongside the growing body of research using Us2.ai in clinical and scientific projects. With new filters across a wide range of topics, there’s something here for everyone, whether you’re diving into the details or simply looking to satisfy your curiosity. A big thank you to every researcher and partner who has contributed. This page is for you too! 👉 us2.ai/clinical-evide…

💲 Reimbursement questions are often the ones that take longest to answer. We've tried to change that. Our new Reimbursement page brings together the information you need, clearly laid out, easy to navigate, and designed to support the conversations happening inside your organisation on reimbursement pathways for echocardiography procedures and AI-enabled coded indications 👉 us2.ai/operations/rei…

💡 We know that bringing new technology into a health system takes more than clinical buy-in. That's why we've built out dedicated IT & Procurement resources on the new website, everything your technical and procurement teams need to evaluate, plan, and move forward with confidence. We've tried to make the process as smooth as possible. Take a look 👉 us2.ai/operations/it-…

📈 𝐍𝐮𝐦𝐛𝐞𝐫𝐬 𝐝𝐨𝐧'𝐭 𝐥𝐢𝐞 𝐚𝐧𝐝 𝐰𝐞'𝐯𝐞 𝐠𝐨𝐭 𝐭𝐡𝐞𝐦. One of our favourite new additions to the website is the Operational Impact page. Real-world data. Real echo labs. Real results. See how Us2.ai is super-powering echo workflows, from turnaround times to reporting efficiency. This is the kind of evidence that matters. 👉 us2.ai/operations/ope…

What does AI-powered echocardiography actually look like in practice? 🤔 Our upgraded website now features dedicated product and feature pages that clearly and visually show how Us2.ai works. Whether you’re exploring for the first time or looking for the details you’ve been missing, this is the place to start. 👉 us2.ai

𝐖𝐞’𝐯𝐞 𝐮𝐩𝐠𝐫𝐚𝐝𝐞𝐝 𝐭𝐡𝐞 𝐔𝐬2.𝐚𝐢 𝐰𝐞𝐛𝐬𝐢𝐭𝐞!  🎉 This is more than a refreshed look. It’s a milestone that reflects how far we’ve come and where we’re headed next. New pages. New data. New resources. All built to showcase the real-world impact of AI-powered echo analysis. We’ll be rolling out highlights over the next week, but if you can’t wait, go take a look now 👀 🔗: us2.ai

🫀 𝐂𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐢𝐬 𝐮𝐧𝐝𝐞𝐫𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐞𝐝 𝐁𝐔𝐓, 𝐀𝐈 𝐜𝐚𝐧 𝐜𝐡𝐚𝐧𝐠𝐞 𝐭𝐡𝐚𝐭. We're proud to share our latest research published in 𝑪𝒊𝒓𝒄𝒖𝒍𝒂𝒕𝒊𝒐𝒏: 𝑪𝒂𝒓𝒅𝒊𝒐𝒗𝒂𝒔𝒄𝒖𝒍𝒂𝒓 𝑰𝒎𝒂𝒈𝒊𝒏𝒈: The development and external validation of Us2's deep learning model for automated detection of cardiac amyloidosis (CA) on echocardiography. Trained on 4,371 patients across the UK and Taiwan, and externally validated in the US and Japan across 5,776 patients in total, the results speak for themselves: ➡️ AUC 0.93 | 88.5% sensitivity | 87.2% specificity ➡️ Robust performance across age, sex, race, amyloid subtype and echo vendor ➡️ Consistently differentiates CA from other hypertrophic phenotypes including HCM, aortic stenosis, hypertension and CKD ➡️ Full report generated in 68 𝐬𝐞𝐜𝐨𝐧𝐝𝐬 Huge thanks to our collaborators at the National Amyloidosis Centre (UCL), Duke University Health System, National Cerebral and Cardiovascular Center (Japan), and MacKay Memorial Hospital (Taiwan). 📄 Read the full paper: us2.ai/clinical-evide… 📩 Contact us to learn more!

Heart disease is the world's #1 killer. Yet one of our most powerful tools for detecting it, the echocardiogram, still relies heavily on manual analysis that's slow and variable. Us2.ai can fix this. Our AI Echo Copilot™ works alongside cardiologists and sonographers to automate the analysis of echocardiograms, delivering 141+ measurements and a fully structured, guideline-directed report. The result? ✔️ Faster diagnoses for patients ✔️ Less burnout for clinical teams ✔️ Greater consistency across health systems ✔️ Earlier detection of conditions like cardiac amyloidosis and heart failure We're already live in hospitals across 30+ countries, FDA-cleared, and CE-marked, and we're just getting started. If you'd like to learn more about what our solution can do, our product brochure is a great place to start. 📄 Take a look: us2.ai/publications/u… or contact us to learn more!

💡 𝐂𝐚𝐫𝐝𝐢𝐚𝐜 𝐀𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐃𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐰𝐢𝐭𝐡 𝐔𝐬2.𝐚𝐢: 𝐃𝐮𝐚𝐥 𝐀𝐈 𝐀𝐩𝐩𝐫𝐨𝐚𝐜𝐡, 𝐅𝐮𝐥𝐥𝐲 𝐄𝐱𝐩𝐥𝐚𝐢𝐧𝐚𝐛𝐥𝐞 FDA-cleared and CE-marked for cardiac amyloidosis detection, Us2.ai is the 𝐎𝐍𝐋𝐘 AI echocardiography solution that combines: ➡️ AI-based pattern recognition detectable from a single apical four-chamber view ➡️ Guideline-aligned, measurement-based automated reporting Our pattern recognition model is trained on a dataset nearly twice the size of prior models and built to differentiate cardiac amyloidosis from clinically similar look-alike conditions. At the same time, our measurement-based approach uses echocardiographic parameters aligned with international clinical guidelines, delivering: ✅ Standardized, evidence-based reporting ✅ Full transparency into how conclusions are derived ✅ Seamless integration into routine echo workflows Speed or explainability? With Us2.ai, you do not have to choose. 👀 See how the findings appear in the AI Echo report below. 📩 Interested in a demo? Get in touch. 📖 Learn more: us2.ai/detection-of-c…

🗣️ 𝐀 𝐧𝐞𝐰 #JACC 𝐓𝐡𝐢𝐬 𝐖𝐞𝐞𝐤 𝐞𝐩𝐢𝐬𝐨𝐝𝐞 𝐡𝐚𝐬 𝐣𝐮𝐬𝐭 𝐝𝐫𝐨𝐩𝐩𝐞𝐝! Co-hosted by our co-founder @lamcardio this episode focuses on Cardiac Amyloidosis... 490 𝐝𝐚𝐲𝐬. That is the median delay to diagnosis reported in recent data. At the same time, mortality benefit in ATTR-CM trials emerges within 12–18 months. The field is moving from 𝑪𝒂𝒏 𝒘𝒆 𝒅𝒊𝒂𝒈𝒏𝒐𝒔𝒆 𝒄𝒂𝒓𝒅𝒊𝒂𝒄 𝒂𝒎𝒚𝒍𝒐𝒊𝒅𝒐𝒔𝒊𝒔? to 𝑯𝒐𝒘 𝒅𝒐 𝒘𝒆 𝒅𝒊𝒂𝒈𝒏𝒐𝒔𝒆 𝒆𝒂𝒓𝒍𝒊𝒆𝒓, 𝒂𝒏𝒅 𝒔𝒚𝒔𝒕𝒆𝒎𝒂𝒕𝒊𝒄𝒂𝒍𝒍𝒚? At Us2.ai, this is exactly the problem we are building for. 𝐎𝐮𝐫 𝐀𝐈 𝐞𝐜𝐡𝐨𝐜𝐚𝐫𝐝𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐢𝐬 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐚𝐧𝐝 𝐨𝐧𝐥𝐲 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐭𝐡𝐚𝐭 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐬 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐭𝐡𝐫𝐨𝐮𝐠𝐡 𝐁𝐎𝐓𝐇: ➡️ Automated, guideline-based chamber quantification and measurements ➡️ AI-driven pattern recognition By combining standardized measurements with disease-pattern analysis, AI can help surface high-risk patients earlier. When disease is progressive and increasingly treatable, systematic detection matters. 🎙️ Listen to the full podcast discussion!

🧡 𝐌𝐚𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐦𝐨𝐬𝐭 𝐨𝐟 𝐇𝐞𝐚𝐫𝐭 𝐇𝐞𝐚𝐥𝐭𝐡 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 𝐌𝐨𝐧𝐭𝐡 🧡 February is #heartmonth, a time to shine a spotlight on the leading cause of death worldwide. Many of us do not realize just how common and preventable heart disease can be. Heart disease affects millions of people every year and carries significant personal and economic costs. While these numbers below are from the U.S., the lessons apply globally. The good news is that small, consistent actions can make a big difference. Awareness, lifestyle choices, and regular check-ups are powerful tools to protect your heart. At Us2.ai, we believe in the power of data to inform better decisions and early detection through AI echo automation. This Heart Health Awareness Month, 𝐰𝐞 𝐰𝐚𝐧𝐭 𝐭𝐨 𝐡𝐞𝐚𝐫 𝐟𝐫𝐨𝐦 𝐲𝐨𝐮. 𝐖𝐡𝐚𝐭 𝐬𝐭𝐞𝐩𝐬 𝐚𝐫𝐞 𝐲𝐨𝐮 𝐭𝐚𝐤𝐢𝐧𝐠 𝐭𝐨 𝐩𝐫𝐨𝐭𝐞𝐜𝐭 𝐲𝐨𝐮𝐫 𝐡𝐞𝐚𝐫𝐭 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐡𝐞𝐚𝐫𝐭𝐬 𝐨𝐟 𝐭𝐡𝐨𝐬𝐞 𝐚𝐫𝐨𝐮𝐧𝐝 𝐲𝐨𝐮? Share your thoughts in the comments 👇

𝐇𝐞𝐚𝐝𝐢𝐧𝐠 𝐭𝐨 𝐖𝐨𝐫𝐥𝐝 𝐇𝐞𝐚𝐥𝐭𝐡 𝐄𝐱𝐩𝐨 𝐢𝐧 𝐃𝐮𝐛𝐚𝐢? Make sure to stop by and meet the Us2.ai team! 👋 We’ll be onsite from 9–12 February with live scanning and a chance to experience firsthand how our cutting-edge AI is redefining echocardiography. 💡 See how Us2.ai can elevate your echo workflow: ✔ Consistent, accurate, and faster echocardiogram analysis ✔ Improved diagnostic efficiency ✔ The latest innovations in cardiovascular imaging 📍𝐘𝐨𝐮 𝐜𝐚𝐧 𝐟𝐢𝐧𝐝 𝐮𝐬 𝐚𝐭 Emerging Global Technologies, 𝐁𝐨𝐨𝐭𝐡 𝐍23.𝐁59. See you at #WHX2026!

🤗 𝐑𝐞𝐚𝐥 𝐢𝐦𝐩𝐚𝐜𝐭 𝐢𝐧 𝐡𝐞𝐚𝐫𝐭 𝐟𝐚𝐢𝐥𝐮𝐫𝐞 𝐜𝐚𝐫𝐞, 𝐚𝐧𝐝 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐨𝐧𝐞𝐬 𝐬𝐚𝐲𝐢𝐧𝐠 𝐢𝐭! It has been encouraging to hear how the BEAT to TREAT heart failure pathway, using point-of-care NT-proBNP testing and 𝐀𝐈-𝐚𝐬𝐬𝐢𝐬𝐭𝐞𝐝 𝐞𝐜𝐡𝐨𝐜𝐚𝐫𝐝𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲, is transforming patient experience and clinical outcomes. Feedback from patients who have attended the clinic at Killie Community Hub so far has been extremely positive, with comments about how the experience feels less stressful and intimidating than attending a regular hospital appointment. For many, this has meant timely access to life-saving medication and a reduced risk of an unplanned hospital admission. Congratulations to @pumpinghearts for leading this initiative and keeping patient experience central to the pathway. It is encouraging to see the impact that collaboration between patient advocacy, clinical leadership, and enabling technologies can have. Us2.ai is grateful to be able to support this work with our technology. 📰 You can read more in the press release here: nhsaaa.net/patients-prais…

𝐀𝐈 𝐢𝐧 𝐞𝐜𝐡𝐨𝐜𝐚𝐫𝐝𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲 𝐢𝐬 𝐚𝐥𝐫𝐞𝐚𝐝𝐲 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐭𝐡𝐞 𝐰𝐚𝐲 𝐰𝐞 𝐮𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝 𝐭𝐡𝐞 𝐡𝐞𝐚𝐫𝐭 🧡 From the moment an image is acquired, through automated measurements and quality checks, to clinician interpretation and structured outputs, AI supports echocardiography workflows in real time. It enhances consistency, surfaces insights that might otherwise be missed, and allows clinicians to focus on what matters most: the patient. This is no longer a vision for tomorrow. AI echo is 𝐚𝐥𝐫𝐞𝐚𝐝𝐲 being used around the world, augmenting expertise and improving cardiovascular care. 📖 For a scientific perspective, this publication carefully explores how AI echo can enhance cardiovascular disease management: us2.ai/publications/a… We want to hear from you. 𝐇𝐨𝐰 𝐢𝐬 𝐀𝐈 𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐞𝐜𝐡𝐨 𝐢𝐧 𝐲𝐨𝐮𝐫 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞, 𝐚𝐧𝐝 𝐰𝐡𝐚𝐭 𝐩𝐨𝐬𝐬𝐢𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬 𝐝𝐨 𝐲𝐨𝐮 𝐬𝐞𝐞 𝐟𝐨𝐫 𝐢𝐭𝐬 𝐫𝐨𝐥𝐞 𝐢𝐧 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐜𝐚𝐫𝐞? Share your thoughts with us below ⬇️